Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy

NCT04620837 ↗

Phase 2 Unknown 25 enrolled Chinese Academy of Medical Sciences

NaSingle-groupOpen-labelTreatment

Summary

To show that maintenance therapy with Tislelizumab plus Anlotinib will prolong Progression Free Survival in subjects with extensive stage disease small cell lung cancer who have completed first line chemotherapy.

Timeline

Start: 2020-11-01
Primary completion: 2022-12-31
Completion: 2023-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Catequentinib	Small molecule	12 mg	Oral
Subject	Tislelizumab	Monoclonal antibody	200 mg	Intravenous

Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy

Summary

Timeline

Drugs

Indications